Emergent BioSolutions Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Emergent is a life sciences company focused on public-health preparedness, with Commercial Products, MCM Products and Bioservices segments. Results are unaudited; interim performance may not indicate full-year results.
Key financial results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue | $300.4 million | $164.3 million |
| Operating income (loss) | $39.8 million | $(147.6) million |
| Net income (loss) | $9.0 million | $(186.2) million |
| Diluted earnings (loss) per share | $0.17 | $(3.71) |
| Cash used in operating activities | $(62.6) million | $(184.0) million |
| Capital expenditures | $10.8 million | $15.1 million |
Revenue increased 83%, led by MCM product sales, which rose to $155.4 million from $37.2 million. Commercial product sales were $118.5 million, up 12%, including $118.5 million of NARCAN sales; Bioservices revenue was $18.5 million, up 28%. Total segment gross margin was $147.8 million, or 51% of segment revenue, versus $4.9 million, or 3%, a year earlier. Services remained loss-making at an $11.8 million gross loss. The filing does not report consolidated operating or net margin as a headline measure; based on reported figures, net margin was approximately 3.0% versus a loss in Q1 2023.
Financial position and liquidity
At March 31, 2024, cash and cash equivalents were $78.5 million ($79.0 million including restricted cash), down from $111.7 million at year-end. Working capital was $52.2 million. Debt principal totaled $909.2 million, including $458.4 million under secured credit facilities and $450.0 million of 3.875% notes due 2028; reported debt carrying value was $905.9 million. The secured facilities mature in May 2025. The company had only $0.3 million of unused revolving capacity at quarter-end. Cash used in operations plus capital expenditures was approximately $73.4 million.
Changes and management commentary
- Higher MCM revenue reflected timing of government and other customer purchases and deliveries: Anthrax MCM sales rose to $55.9 million, Smallpox MCM to $50.2 million, and Other Products to $49.3 million. Management cautions that MCM sales fluctuate with government funding, purchase options and delivery timing.
- NARCAN sales increased 18%, primarily on higher U.S. public-interest channel and OTC sales. Commercial gross margin was 56%, down one percentage point, partly reflecting OTC product mix.
- Bioservices costs fell 41% amid lower overhead and limited facility activity, but the segment still recorded a negative 64% gross margin. Management had previously reduced investment in and de-emphasized Bioservices.
- R&D expense fell 63% to $15.1 million and SG&A fell 16% to $84.7 million, mainly reflecting prior restructuring and lower corporate costs; higher NARCAN marketing and legal fees partly offset SG&A savings.
Outlook, risks and unusual items
- Going concern: Management concluded substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the statements. Its proposed mitigations—including further debt amendments, improved operations, working-capital reductions and asset sales—were not considered probable at the reporting date.
- Debt amendment after quarter-end: On April 29, 2024, lenders agreed to a Seventh Amendment. It raises borrowing margins, reduces revolving commitments in stages to $200 million from October 31, 2024, and requires at least $85 million of equity or unsecured debt by July 31, 2024, subject to a possible extension and offsets for qualifying asset-sale proceeds. New monthly EBITDA, capital-spending and minimum-liquidity requirements apply. The company says there is no assurance it can meet the capital-raise requirement. Default could accelerate secured debt and trigger cross-defaults under the 2028 notes, potentially forcing insolvency proceedings.
- The company’s ATM program was unavailable for sales at quarter-end because of prior delayed SEC filings; it said eligibility requires 12 consecutive months of timely periodic filings. This limits a potential source of financing.
- On May 1, 2024, the company announced a further restructuring: approximately 300 employee reductions, elimination of about 85 vacant positions, and closure of two Maryland manufacturing facilities. Estimated charges are $18–$21 million, primarily expected in Q2 2024.
- A $158.8 million long-term asset balance relates to the disputed Janssen manufacturing agreement. The company is in confidential arbitration, has recorded no liability for Janssen’s allegations, and cannot reasonably estimate possible litigation losses generally. Securities and derivative lawsuits and government inquiries related to past manufacturing capabilities also remain outstanding.
- Management provided no quantified full-year revenue or earnings guidance in the supplied filing text. It expects quarterly results to remain variable. Other key risks include government procurement and funding, manufacturing quality and regulatory compliance, customer collections, competition in OTC NARCAN, and the ability to service and refinance debt.
Most important facts for investors to verify
- Whether Emergent raises the required capital or applies qualifying asset-sale proceeds by the amended deadline, and complies with the new liquidity and financial covenants.
- Cash runway, operating cash burn, working-capital collections and the practical availability of financing or asset sales; quarter-end revolving availability was only $0.3 million.
- Whether restructuring delivers sustainable cost savings without impairing product supply, revenue or future cash generation, including the impact of the two facility closures.
- Timing and durability of government MCM orders and NARCAN OTC sales, and whether Bioservices can reduce its continuing losses.
- Progress and potential financial outcomes of the Janssen arbitration and shareholder litigation, including recoverability of the $158.8 million Janssen-related asset balance.